Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All antiandrogen studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchAntiandrogensAntiandrogens (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Finasteride in hospitalized adult males with COVID-19: A risk factor for severity of the disease or an adjunct treatment: A randomized controlled clinical trial

Zarehoseinzade et al., Medical Journal of The Islamic Republic of Iran, doi:10.47176/mjiri.35.30
Apr 2021  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Mortality 75% Improvement Relative Risk ICU admission 0% Finasteride  Zarehoseinzade et al.  LATE TREATMENT  RCT Is late treatment with antiandrogens beneficial for COVID-19? RCT 80 patients in Iran Lower mortality with antiandrogens (not stat. sig., p=0.36) c19early.org Zarehoseinzade et al., Medical J. The .., Apr 2021 Favorsfinasteride Favorscontrol 0 0.5 1 1.5 2+
7th treatment shown to reduce risk in September 2020
 
*, now with p = 0.000000056 from 49 studies.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,500+ studies for 81 treatments. c19early.org
RCT 80 hospitalized COVID-19 patients in Iran, 40 treated with finasteride, showing no significant differences other than improved oxygen saturation on the 5th day with treatment. There was significantly more patients with diabetes in the control group. 5mg finasteride for 7 days. IRCT20200505047318N1.
risk of death, 75.0% lower, RR 0.25, p = 0.36, treatment 1 of 40 (2.5%), control 4 of 40 (10.0%), NNT 13.
risk of ICU admission, no change, RR 1.00, p = 1.00, treatment 1 of 40 (2.5%), control 1 of 40 (2.5%).
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Zarehoseinzade et al., 30 Apr 2021, Randomized Controlled Trial, Iran, peer-reviewed, 5 authors.
This PaperAntiandrogensAll
Finasteride in hospitalized adult males with COVID-19: A risk factor for severity of the disease or an adjunct treatment: A randomized controlled clinical trial
Elham Zarehoseinzade, Abbas Allami, Mehrnoosh Ahmadi, Behzad Bijani, Navid Mohammadi
Medical Journal of The Islamic Republic of Iran, doi:10.47176/mjiri.35.30
Background finasteride mig COVID-19 infe Methods: W patients aged ≥ patients were r drug therapy an and secondary protocol was IR.QUMS.REC significant. Results: We (p= 0.018). Th patients in the f Conclusion: hospitalized m required to help
staff at the B in the study. Conflict of I The authors d
References
Adamowicz, reductase inhi Med Hypothes
Chen, Xu inducible fact transition in
Goren, J, C Mesinkovska N with Reduced Androgenetic, Dermatol
Goren, Mcc, What An insight into
Guan, None, Ni characteristics
Hoffmann, Erichsen, None, Cell
Li, Huang, -19 pa rate of meta-an
Mehta, Mca, None, C immunosuppre
Mikkonen, None, Endocrinol
Moran, Jones, Sharafi, S, outcome of co and over. Int J 14. Hayes AF, P Quantification
Temgoua Mn Belobo, Et, screening of Middle-Incom, Med J
Wambier, Nau, None, Drug
{ 'indexed': {'date-parts': [[2022, 3, 31]], 'date-time': '2022-03-31T02:29:37Z', 'timestamp': 1648693777420}, 'reference-count': 0, 'publisher': 'Academic World Research', 'content-domain': {'domain': ['www.mjiri.iums.ac.ir'], 'crossmark-restriction': False}, 'short-container-title': ['mjiri'], 'DOI': '10.47176/mjiri.35.30', 'type': 'journal-article', 'created': {'date-parts': [[2021, 6, 6]], 'date-time': '2021-06-06T11:16:01Z', 'timestamp': 1622978161000}, 'update-policy': 'http://dx.doi.org/10.47176/mjiri/crossmark_policy', 'source': 'Crossref', 'is-referenced-by-count': 3, 'title': [ 'Finasteride in hospitalized adult males with COVID-19: A risk factor for severity of the ' 'disease or an adjunct treatment: A randomized controlled clinical trial'], 'prefix': '10.47176', 'author': [ {'given': 'Elham', 'family': 'Zarehoseinzade', 'sequence': 'first', 'affiliation': []}, {'given': 'Abbas', 'family': 'Allami', 'sequence': 'additional', 'affiliation': []}, {'given': 'Mehrnoosh', 'family': 'Ahmadi', 'sequence': 'additional', 'affiliation': []}, {'given': 'Behzad', 'family': 'Bijani', 'sequence': 'additional', 'affiliation': []}, {'given': 'Navid', 'family': 'Mohammadi', 'sequence': 'additional', 'affiliation': []}], 'member': '26714', 'published-online': {'date-parts': [[2021, 4, 30]]}, 'container-title': ['Medical Journal of The Islamic Republic of Iran'], 'original-title': [], 'link': [ { 'URL': 'http://mjiri.iums.ac.ir/article-1-7160-en.pdf', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2021, 6, 6]], 'date-time': '2021-06-06T11:16:25Z', 'timestamp': 1622978185000}, 'score': 1, 'resource': {'primary': {'URL': 'http://mjiri.iums.ac.ir/article-1-7160-en.html'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2021, 4, 30]]}, 'references-count': 0, 'URL': 'http://dx.doi.org/10.47176/mjiri.35.30', 'relation': {}, 'ISSN': ['1016-1430', '2251-6840'], 'issn-type': [{'value': '1016-1430', 'type': 'print'}, {'value': '2251-6840', 'type': 'electronic'}], 'subject': ['General Medicine'], 'published': {'date-parts': [[2021, 4, 30]]}}
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit